Innovent Biologics's total assets for Q2 2025 were ¥23.59B, an increase of 9.22% from the previous quarter. HK:1801 total liabilities were ¥9.17B for the fiscal quarter, a 8.10% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.